Valeant Pharmaceuticals International Inc., Canada’s largest drugmaker, is close to acquiring Bausch & Lomb Holdings Inc., the eye-care company owned by Warburg Pincus LLC, for about $9 billion, said a person with knowledge of the negotiations.
Actavis Inc.’s $5 billion deal to buy Warner Chilcott Plc brings in a new stable of brand-name women’s health drugs. It also comes with headquarters relocated to Ireland and lower taxes for the combined company.
The Standard & Poor’s 500 Index retreated from a record amid concern the Federal Reserve will scale back its stimulus efforts. Gold and silver advanced as Moody’s Investors Service warned the U.S. rating may be cut. The yen rebounded from the weakest level since 2008.
Teva Pharmaceutical Industries Ltd. resumes trading today in Tel Aviv at the biggest discount to New York in 2 1/2 years after the prospect of acquisitions among generic-drug makers fueled gains in its U.S.-traded stock.
Actavis Inc. rejected a cash-and- stock offer from fellow generic-drug maker Mylan Inc. for about $15 billion, deciding instead to pursue talks to take over Warner Chilcott Plc, said people familiar with the matter.